Fennec Pharmaceuticals (FENC)
NASDAQ:FENC
FENC Stock Chart & Stats
$6.79
-$0.02(-0.33%)
At close: 4:00 PM EST
$6.79
-$0.02(-0.33%)
Day’s Range― - ―
52-Week Range$5.65 - $10.45
Previous Close$6.08
Volume58.66K
Average Volume (3M)330.56K
Market Cap
$312.63M
Enterprise Value$243.62M
Total Cash (Recent Filing)$40.08M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 06, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding34,737,030
10 Day Avg. Volume236,537
30 Day Avg. Volume330,563
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)6.29
Price to Sales (P/S)4.86
P/FCF Ratio-15.03
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue4.76
Enterprise Value/Gross Profit5.16
Enterprise Value/Ebitda-42.63
Forecast
1Y Price Target
$15.50Price Target Upside128.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.26
Revenue Forecast (FY)$67.27M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue AccelerationRepeated quarterly sales gains and a 73% YoY jump in Q1 demonstrate durable commercial traction for PEDMARK. Consistent growth across multiple quarters implies expanding prescriber adoption and repeat utilization, which supports predictable revenue scaling as the company broadens reach and converts target prescribers.
Very High Gross MarginsA ~92% gross margin indicates strong product economics typical of specialty biopharma, providing a durable source of profitability as revenue scales. High gross margins allow the company to absorb commercial investments and potentially generate operating leverage if fixed costs stabilize and adoption continues to rise.
Delevered, Strengthened Balance SheetElimination of debt materially reduces insolvency and interest burden risk, giving management flexibility to fund commercialization and R&D from equity and cash. A stronger capital structure improves resilience to seasonal cash swings and supports strategic options like partnerships or selective investment in market expansion.
Bears Say
Negative Operating And Free Cash FlowRenewed negative operating and free cash flow drains reserves and raises the probability of future financing if profitability does not improve. Persistent cash burn undermines long-term self‑funding assumptions and increases dependency on timing of revenues, partner milestones, or capital markets to sustain commercial expansion.
High, Front‑loaded 2026 OpExMaterial, front‑loaded operating spending concentrates near‑term cash outflows and magnifies quarter-to-quarter liquidity variability. If revenue ramp or expected partner receipts lag, elevated H1 spend could force cuts, slower hiring or external funding, all of which would impair execution of the commercial scale-up plan.
Single-product ConcentrationHeavy dependence on one product for U.S. sales concentrates commercial, regulatory and reimbursement risk. Limited labeled pediatric indications constrain total addressable market and revenue diversification, so setbacks in adoption, coverage changes, or competitive entrants could materially impair long-term growth prospects.
Fennec Pharmaceuticals News
FENC FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was $5.65 and its highest was $10.45 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is $312.63M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 50 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on May 14, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.044 by $0.054.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.02.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 34,737,030 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.044. Following the earnings report the stock price went up 36.484%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in FENC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (128.28% Upside)
$15.50 (128.28% Upside)
Blogger Sentiment
Bullish
FENC Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.88%
12-Months-Change
Fundamentals
Return on Equity
-55.13%
Trailing 12-Months
Asset Growth
54.78%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc., a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation currently undergoing clinical development. This product candidate is specifically engineered to protect young cancer patients from platinum-induced ototoxicity, a form of hearing loss caused by chemotherapy. Previously known as Adherex Technologies Inc., the company officially rebranded to Fennec Pharmaceuticals Inc. in September 2014.
FENC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple material commercial and clinical positives: strong top-line acceleration (+73% YoY), meaningful operational traction from the Fennec HEARS hub (48% QoQ infusion increase, 80% conversion and adherence), expanded commercial reach (prescriber targets expanded from ~1,300 to >5,000) and growing clinical momentum via ISTs and ASCO visibility. Counterbalancing these positives are higher near-term operating expenses (~$14M in Q1, ~$50M expected for 2026 with front-loaded spend), some near-term cash seasonality with Q2 expected to be lower than Q1, and a missed German milestone from partner Norgine. Overall, the highlights and catalysts materially outweigh the lowlights, with management emphasizing that cash plus projected revenues should fund operations and that commercial investments are already showing early returns.View all FENC earnings summariesFENC Stock 12 Month Forecast
Average Price Target
$15.50
▲(128.28% Upside)
Technical Analysis
Satellos Bioscience
―
Helix BioPharma
―
―
Eupraxia Pharmaceuticals
―
ME Therapeutics Holdings, Inc.
―
Ownership Overview
10.28% Insiders
4.53% Mutual Funds
― Other Institutional Investors
79.09% Public Companies and
Individual Investors